Yizhe Wu
Head of Drug Discovery HealZen Therapeutics Co., Ltd.
Seminars
Wednesday 9th September 2026
Advancing Next-Generation Pan-RAS Targeting for Broad & Durable Control of RAS-Driven Cancers
2:00 pm
- Mapping the global pan-RAS competitive landscape and defining remaining biological and clinical gaps beyond first-generation RAS(ON) and allele-selective inhibitors, highlighting opportunities for differentiated therapeutic strategies
- Leveraging a proprietary molecular-glue discovery platform to identify distinct PPI and enabling identification of differentiated next-generation pan-RAS inhibitors with best-in-class potential
- Demonstrating the therapeutic promise of Healzen Therapeutics’ pan-RAS program through key preclinical insights and program highlights supporting broad activity, improved durability, and competitive differentiation across RAS-driven cancers
